ValiRx plc (VAL.L)

GBp 0.53

(4.63%)

Market Cap (In GBp)

1.96 Million

Revenue (In GBp)

9600.00

Net Income (In GBp)

-2.03 Million

Avg. Volume

5.02 Million

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.7-6.3
PE
-0.26
EPS
-0.02
Beta Value
0.536
ISIN
GB00BLH13C52
CUSIP
G9313Z140
CIK
-
Shares
374349000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D.
Employee Count
-
Website
https://www.valirx.com
Ipo Date
2002-01-07
Details
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.